Treatment of inoperable stage III and IV non-small-cell lung cancer: The 'average' radiotherapist's point of view

Onkologie

Volumn 24, Issue 4, 2001, Pages 333-339

  Plataniotis, G A ^a   Theofanopoulou, M A ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Chemotherapy (radical, palliative); Non small cell lung cancer (NSCLC); NSCLC, stage III, IV; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; VINBLASTINE;

BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; ESOPHAGITIS; GERIATRIC PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; META ANALYSIS; PROGNOSIS; RADIATION DOSE FRACTIONATION; REVIEW; SIDE EFFECT; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PALLIATIVE CARE;

EID: 0035743302     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055104     Document Type: Review

References (34)

1. Stage III NSCLC: Still a challenge for the radiation oncologist
2. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology (RTOG) studies in inoperable NSCLC
3. The clinical evaluation of chemotherapeutic agents in cancer
4. The benefit of treatment intensification is age and histology dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies
5. Radiotherapy for NSCLC: Fractionation and cost-effectiveness
6. Promising survival with three dimensional conformal radiation therapy for non-small-cell lung cancer
7. Radiotherapy for lung cancer: Target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation
8. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced NSCLC: Comparison of RTOG 83-11 and RTOG 91-06
9. Experience with dose escalation using CHARTWELL (CHART weekend Less) in NSCLC
10. Continuous, hyperfractionated, accelerated radiotherapy (CHART) vs conventional radiotherapy in NSCLC: Mature data from the randomized multicentre trial
11. Chemotherapy in NSCLC: A meta-analysis using updated data on individual patients patients from 52 randomized clinical trials
12. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III NSCLC
13. Is concomitant cisplatin and radiotherapy more efficacious treatment than radiotherapy alone in stage III NSCLC?
14. Induction cisplatin/vinblastine and irradiation vs irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588
15. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of the lung (NSCCL): Analysis of radiation therapy oncology group (RTOG) trials
16. RTOG 88-08 and ECOG 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer
17. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III NSCLC
18. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III NSCLC: A randomized study
19. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable NSCLC: RTOG 92-04
20. ASTRO plenary: Effect of chemotherapy on locally advanced NSCLC: A randomized study of 353 patients
21. Improved survival in stage III NSCLC: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
22. Radio-sensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer: A phase III trial of the cancer and leukemia group B and Eastern cooperative oncology group
23. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable NSCLC: RTOG Protocol 91-06
24. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable NSCLC: A hoosier oncology group protocol
25. Alternating radiotherapy and chemotherapy for inoperable stage III NSCLC: Long-term results of two-phase II GOTHA trials
26. Effects of concomitant cisplatin and radiotherapy on inoperable NSCLC
27. Response, toxicity, failure patterns and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung
28. Inoperable non-small-cell lung cancer: A MRC randomized trial with two fractions or ten fractions
29. A medical research council (MRC) randomized trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer and poor performance status
30. A short course of palliative radiotherapy for inoperable NSCLC: Biologically effective dose to the spinal cord
31. Radiation myelitis and thoracic radiotherapy: Evidence and anecdote
32. Randomized trial of palliative two-fractions versus more intensive 13-fraction radiotherapy for patients with inoperable NSCLC and good performance status
33. Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy? Analysis of the radiation therapy oncology group experience
34. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer